One of every four visits to eye care professionals is for dry eye disease which affects an estimated 7-34% of Americans [1] . Knowledge regarding etiology and treatments has advanced exponentially in the last 20 years. As recently as 1997, in the mega textbook Cornea, it was stated "The mechanism for lacrimal gland dysfunction in this condition is unclear" [2] . A recent study entitled "The Dry Eye Workshop ll Report", de ines dry eye as "a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear ilm and accompanied by ocular symptoms in which tear ilm instability and hyperosmolarity, ocular surface in lammation, and damage and neurosensory abnormalities play etiological roles" [3] . A 2003 study regarding the morbidity ratings of dry eye showed utility assessments for moderate and severe dry eye were parallel to historical reports for more severe (class lll/ lV) angina [4] . The tear ilm is responsible for the greatest optical power of any ocular surface, since the greatest change in the index of refraction occurs between the air and the tear ilm [5] . Double pass retinal imaging shows increased light scatter in dry eye patients which can decrease retinal image quality 20-40% [5] . Ophthalmologists now understand the critical necessity to normalize the ocular surface prior to cataract surgery; otherwise, they risk an unhappy patient with a less than ideal visual result. Increased use of electronic devices, such as smart phones, tablets, and computers, by youth in the last ten years has resulted in a broader age range of dry eye patients, to now include adolescents and teens. A study of urban school age children showed that 8.2% had dry eye (vs 2.8% in a rural group), presumably due to high incidence of smart phone use. 6 In fact, with cessation of phone use for four weeks, dry eye resolved completely in 100% of subjects [6] . Only two FDA approved dry eye medications are available: cyclosporine ophthalmic emulsion, 0.05%, (approved in 2003) and li itegrast, 5%, (approved in 2016), both of which require chronic treatment. The focus of this discussion involves an emerging paradigm in treating ocular surface disease: a nutraceutical containing omega-3 essential fatty acids.
Dry eye disease may be broadly characterized as aqueous de icient (quantity) or evaporative (quality). In one large study, 86% of patients with dry eye disease had an evaporative component due to meibomian gland disease, (MGD) [7] . The Meibomian glands secrete meibum, the oil stabilizing the tear ilm, essential for a normal tear break up time and a moist cornea. MGD is characterized by terminal duct obstruction and/or qualitative/ quantitative changes in glandular secretion. Clinical signs include foam formation at the lid margin due to break down of lipids from soaps to free fatty acids (saponi ication), a toothpaste-like secretion upon attempted gland expressionalso seen by meibomography, and a rapid tear break up time (TBUT).
Dietary patterns present for hundreds or thousands of years have changed in recent times. Essential fatty acids, only available through ingested food, fall into two major groups, Omega-3 and Omega-6 fatty acids, and are a requirement for multiple biological processes in the body. The ideal ratio in the body of Omega-3/6 is 1/1 but with contemporary diets rich in animal fats, vegetable oils and processed foods, a common ratio is 1:20 or higher [8] . Key omega-3s including DHA (Docosahexaenoic acid) and EPA (Eicosapentaenoic Acid) are found in ish, laxseed, walnuts, and avocados. They foster mental acuity, a healthy nervous system, immunity, regular heart rhythm, healthy heart growth, and reduction in in lammation, blood clots, serum triglycerides, and LDL cholesterol [9] .
Among the early work (2000) supporting the ef icacy of Omega-3's for dry eye, Carol Boerner, MD, followed 200 patients on 2,000 mg of laxseed oil for three years. Symptoms improved in 85% [10] . An Association for Research in Vision and Ophthalmology (ARVO) presentation in 2003 by Trivedi, Sana, Gilbard, et al. summarized the Harvard Women's Health Study involving 39,876 patients. Results showed that the more tuna ish consumed, the lower the risk of dry eye: 2-4 servings/ week cut risk by 18% (compared to less than 2), and 5-6 servings/ week reduced risk by 66%. Not mentioned was the increased risk of mercury poisoning. In 2007 Athena Papas, DMD, et al. from Tufts University presented data at ARVO showed that utilizing an omega-3 supplement containing ish oil, laxseed oil and vitamin E (Thera-tears Nutrition), resulted in signi icant reduction in symptoms of dry eye and dry mouth associated with Sjogren's syndrome (61 patients). Another study presented at ARVO in 2012 and sponsored by Science Based Health analyzed administration of omega-3 and gamma linolenic acid (Hydro Eye) for 6 months in 38 postmenopausal women. Improvements were noted in patient's symptoms (ocular surface disease index) and impression cytology in lammatory biomarkers, but no improvements were noted in corneal staining or tear breakup time.
A comparative study of three omega-3 preparations was reported by Frank Bucci, et al., at the American Academy of Ophthalmology meeting, 2011. This multicenter blinded randomized 3 month clinical study of 60 patients compared three oral supplements: PRN Dry Eye Omega Bene its, Nature made and Thera-tears [11] . Red blood cell membrane saturation index of Omega-3, EPA and DHA were measured [11] . The PRN preparation achieved desirable therapeutic levels of 8% after 1 month of use in 44% of patients, up from 4% at baseline; (measured by a simple inger stick blood test: Omega Quant, Sioux Falls, SD) [11] . Average values at 3 months were PRN 7.75%, Nature made 6.6%, and Thera-tears 5.9% [11] .
All Omega-3 preparations are not created equal, relative to quality, purity and ef icacy. One important difference is the chemical form inalized by the manufacturing process. The most pristine natural source of EPA and DHA is from pelagic ish in the Tasman Sea. Unfortunately, virtually all commercially obtained ish oil is contaminated by mercury and carcinogens. Processing requires the use of alcohol or ethyl ester to purify this mix, but two undesirable sequelae ensue. The human body is poorly able to tolerate this foreign chemical alcohol leading to " ishy" side effects (dyspepsia) and perhaps more importantly, poor systemic absorption. For example a pill alleging 500mg of omega-3 in the ethyl ester form may only deliver 200mg. Furthermore, some OTC ish oil preparations in a water illed foam cup completely dissolve the cup bottom within several minutes. In order to remove the alcohol portion from the ish oil, a time consuming re-esteri ication process converts the product to its' original triglyceride form. This has proven to yield superior absorption [12] . The desirable value of 8% is known to be cardio-protective. Achieving a signi icant serum level was noted in a study over 20 years ago to reduce the risk of sudden death by myocardial infarction by 90% [13] . Depending on a person's weight and diet, an average dosage of 2 grams EPA and DHA daily for 2-3 months will likely achieve the desired level. Although laxseed oil has some bene it due to abundant Omega-3's, it also contains alpha linoleic acid. ALA is partially metabolized to arachidonic acid, a pro-in lammatory product.
Even with incomplete understanding of their mechanism of action, Omega-3 essential fatty acids were recommended as irst line therapy by both the Dry Eye Workshop study group in 2007 and the International Workshop on Meibomian Gland Dysfunction in 2011 [14, 15] . MGD is associated with altered lipid composition leading to increased tear evaporation and elevated tear osmolarity and subsequent ocular surface damage, epithelial cell desiccation, apoptosis and symptoms of burning and discomfort. High quality Omega-3 supplementation increases levels of unsaturated fatty acids in meibomian secretions which in a liquid state at room temperature prevent the blockage and stagnation within meibomian ori ices. Thus tear ilm evaporation decreases, tear breakup time increases, and dry eye signs and symptoms improve. Additional bene its are decreased in lammation and increased tear secretion (by elevating CAMP).
An important feature of dry eye is in lammation and this condition, when associated with Omega-3 de iciency, can be linked to multiple other systemic illnesses. Many patients in the western world with dry eye also have age-related macular degeneration. In Japan these two conditions are virtually nonexistent due to a diet rich in Omega-3 EFA's. Cardiovascular studies have shown strong bene its linking omega-3 ingestion with reduced risk of cardiovascular disease [16, 17] . These bene its include increased arterial elasticity, decreased erythrocyte "stickiness", decreased arrhythmias, decreased in lammation and decreased serum triglycerides. Young and middle aged patients with MGD have higher cholesterol levels than controls of similar age without MGD [18] . A 2016 study found that two large servings of oily ish / week reduced the risk of diabetic retinopathy by 48% [19] . Recent research has identi ied a new class of signaling molecules called resolvins. Derived from DHA and EPA, these compounds are necessary components of the endogenous system which acts as the "off-switch" for the normal in lammatory response [20] .
Perhaps the most thorough and widely read study on the ef icacy of omega-3's appeared in Cornea, Sept., 2016, and analyzed the effects of a re-esteri ied triglyceride form in 105 patients [21] . This was a multicenter, prospective, interventional, placebo controlled, double masked study [21] . Subjects took 4 soft gels daily containing a total of 1680mg of EPA/560mg of DHA (Dry Eye Omega bene its, Physicians Recommended Nutraceuticals) or a control of 3136mg of linoleic acid daily for 12 weeks [21] . The conclusion was a statistically signi icant improvement in each of ive parameters measured: Ocular Surface Disease Index score (patient's symptomatology), tear osmolarity, MMP-9 (an in lammatory marker), omega-3 serum index levels, and tear break up time [21] .
Recent advances in knowledge regarding omega-3 essentials fatty acids will improve patient care both in dry eye disease and the rest of medicine. Two prescription oral omega-3 preparations are presently available: Lovaza (Omega-3-ethyl esters) and Vascepa (icosapent ethyl), a re-esteri ied triglyceride. The great majority of OTC omegas-3's are in the less desirable ethyl ester or alcohol form. A 2006 publication stated omega-3 de iciency or omeganemia was responsible for 96,000 deaths a yr. making it the sixth leading preventable cause of death in the United States [22] . Regarding dry eye and multiple other conditions, the happier category of patients are those with mild-moderate disease who become asymptomatic with treatment [22] . All patients begin at stage one; it is more dif icult and less satisfying to treat advanced disease.
Finally at least two myths persisting about omega 3 essential fatty acids should be dispelled. First, patients on omega-3's EFA's are more prone to bleeding. This is true for most OTC brands due to the persistence of chemicals used to eliminate containments and pollutants. When these chemical are removed, the re-esteri ied triglyceride form is both digestible and not associated with hematologic abnormalities. Second, one article linked Omega-3's to prostate cancer [23] . This of course made national headlines and the nightly news. Prior studies involving over 500,000 subjects have shown a reduction in prostate cancer. The study was seriously lawed in many ways and was later retracted [24] . Unfortunately, bad information was falsely sensationalized, and the correction never made the front page.
Dry eye has a high impact on quality of life due to discomfort and/or visual disability. In a typical eye care practice, dry eye is the single most common complaint for patients seeking care. In both Dry Eye Workshop Study (DEWS) I & II reports from 2007 and 2017 respectively, nutritional therapy is listed as irst line treatment for even mild dry eye. Evidence for bene its of nutritional supplementation continues to mount. Chinnery, et al. found that Omega-3 supplementation imparts neuroprotective effects in the cornea sub-basal plexus which correlate with improvement in tear osmolarity [25] . In another study, rosacea patients showed improvement in symptoms, TBUT, Schirmer score and Meibomian gland score (MGS) with six months of Omega 3 supplementation [26] . An of ice-based study involving 1,419 patients in Spain found multiple bene its in dry eye sufferers utilizing a supplement that contained a combination of Omega-3 fatty acids, vitamins, minerals, and antioxidants [27] . A systematic review of ifteen independent studies involving 2,591 patients who used supplements with varying amounts of Omega-3 and Omega-6 EFA's was published in March, 2017 [28] . Subjective symptom improvement was noted in seven of the studies and TBUT signi icantly increased in nine of the studies [28] . One reason for the variable results is the variation in levels of Omegas in each supplement. While the AREDS II study failed to show statistical bene it for adding omega 3 EFA's, it was most likely because the less desirable form (ethyl ester) and a suboptimal dose of 1 gram, (350mg DHA and 650mg EPA), were used [29] . The data is convincing that supplementation with high quality Omega-3 essential fatty acids (re-esteri ied triglyceride), in the proper dosage, is a starting point for treating this frustrating and potentially debilitating condition.
